Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844255 | 0.84 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2LMNAKMT2ACD274 | |
| SCHEMBL12844562 | 0.82 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2LMNAKMT2ACD274 | |
| SCHEMBL12775340 | 0.81 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2LMNAKMT2ACD274 | |
| SCHEMBL12986916 | 0.80 | CD274 (0.59) | ALDH1A1CD274HTR1AMAOAMAOB | |
| SCHEMBL13689965 | 0.79 | ENPP2 (0.58) | ALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL12057374 | 0.77 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2LMNAKMT2ACD274 | |
| SCHEMBL12017916 | 0.76 | TP53 (0.42) | ALDH1A1SMN1; SMN2LMNAKMT2APOLB | |
| SCHEMBL12017920 | 0.75 | POLB (0.43) | ALDH1A1SMN1; SMN2LMNAKMT2APOLB | |
| SCHEMBL12012694 | 0.75 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2LMNAKMT2ACD274 | |
| SCHEMBL178529 | 0.75 | CD274 (0.74) | ALDH1A1LMNACD274HTR1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | ALDH1A1 134/4885SMN1; SMN2 1483/4885LMNA 1611/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ALDH1A1 148/4885SMN1; SMN2 1371/4885LMNA 1093/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | ALDH1A1 134/4885SMN1; SMN2 1483/4885LMNA 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.